ARS Pharmaceuticals, Inc (SPRY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $391.06M
Last updated: Nov 17, 2026 at 11:06 AM ET
ARS Pharmaceuticals, Inc (SPRY) Stock Forecast
Analysts expect ARS Pharmaceuticals (SPRY) to earn -$1.87 per share in the fiscal year ending Dec 31, 2026, on revenue of $121.42M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 40.1%.
- Fiscal year ending Dec 31, 2026
- -$1.87
- EPS consensus, revenue $121.42M
- Fiscal year ending Dec 31, 2027
- -$0.86
- EPS consensus, revenue $170.09M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.87 | -$1.89 to -$1.85 | 2 | $121.42M | $116.33M to $125.10M | 4 |
| Dec 31, 2027 | -$0.86 | -$0.97 to -$0.71 | 3 | $170.09M | $142.06M to $202.21M | 4 |
Quarterly Estimates
The EPS consensus falls from -$0.31 for the quarter ending Dec 31, 2026 to -$0.34 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.31 | -$0.41 to -$0.17 | 6 | $28.65M | $24.01M to $32.66M | 6 |
| Mar 31, 2027 | -$0.34 | -$0.41 to -$0.27 | 2 | $24.54M | $24.50M to $24.58M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 2 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.72.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.87 | -$1.88 | -$1.87 | -$1.84 | -$1.72 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.86 | -$0.90 | -$0.90 | -$0.89 | -$0.94 | N/A |
| Quarter ending Mar 31, 2027 | -$0.34 | -$0.39 | -$0.39 | -$0.39 | -$0.25 | N/A |
Frequently Asked Questions About SPRY
What is the SPRY stock forecast?
Consensus analyst estimates put ARS Pharmaceuticals's EPS at -$1.87 for the fiscal year ending Dec 31, 2026, on revenue of $121.42M. The consensus rating from 4 analysts is Buy.
How do analysts rate SPRY stock?
Of 4 analysts covering ARS Pharmaceuticals, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SPRY next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.87, with estimates from -$1.89 to -$1.85 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.86, with estimates from -$0.97 to -$0.71 from 3 analysts.
What revenue do analysts expect from ARS Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $121.42M, with estimates from $116.33M to $125.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $170.09M, with estimates from $142.06M to $202.21M.
How many analysts cover SPRY?
4 analysts rate ARS Pharmaceuticals stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SPRY pages: Overview, Earnings, Forecast, Financials, Competitors